Skeletal Muscle Mass Loss During Cancer Treatment: Differences by Race and Cancer Site.

OBJECTIVES: To examine skeletal muscle mass change in a racially diverse sample of patients undergoing cancer treatment, determine significant predictors of muscle mass loss, and explore the interaction of race and cancer site. SAMPLE & SETTING: A retrospective analysis was conducted for 212 patient...

Descripción completa

Detalles Bibliográficos
Publicado en:Oncology Nursing Forum Vol. 47; no. 5; pp. 557 - 567
Autores principales: Min Kyeong Jang, Chang Gi Park, Susan Hong, Laddu, Deepika, Hongjin Li, Rhee, Esther, Doorenbos, Ardith Z.
Formato: research tables/charts Journal Article
Publicado: Oncology Nursing Society Sep2020
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:OBJECTIVES: To examine skeletal muscle mass change in a racially diverse sample of patients undergoing cancer treatment, determine significant predictors of muscle mass loss, and explore the interaction of race and cancer site. SAMPLE & SETTING: A retrospective analysis was conducted for 212 patients seeking treatment at a university hospital clinic. METHODS & VARIABLES: Skeletal muscle mass index (SMI) was determined by computed tomography at the time of cancer diagnosis and with cancer treatment. RESULTS: One hundred thirty-four patients (63%) had SMI loss with cancer treatment. Race and cancer site were found to be significant predictors of SMI loss. Compared to other racial groups, non-Hispanic Black (NHB) patients had the greatest SMI loss (p < 0.001) with cancer treatment. NHB patients with rectal cancer experienced the greatest SMI loss compared to patients of other races and cancer types. IMPLICATIONS FOR NURSING: To improve survivorship care for patients with cancer, it is essential to develop strategies for assessing and managing skeletal muscle mass loss throughout treatment, particularly for NHB patients with rectal cancer.